

# Clinical Decision Support Technologies for Oncologic Pathology

Brian H. Shirts

Assistant Professor, Department of Laboratory Medicine  
University of Washington,

National Cancer Policy Forum

Improving Cancer Diagnosis and Patient Care Workshop

Feb 12, 2018

# Clinical Decision Support (CDS)

Information presented to assist clinicians in appropriately interpreting and acting on diagnostic testing results.

“...knowledge and person-specific or population information, intelligently filtered or presented at appropriate times, to foster better health...”

# CDS for Guidelines and Appropriate Use

- ▶ Guidelines can take years to disseminate
- ▶ Even with effective dissemination, implementation may be variable
- ▶ Clinical decision support can be an ideal way to:
  - ▶ Educate
  - ▶ Remind
  - ▶ Assist


# Passive and Active CDS

- ▶ Passive – require user effort to access or interpret
  - ▶ Reference ranges
  - ▶ Dose or risk calculators
  - ▶ URLs with links to additional information
  - ▶ [Infobuttons](#)
- ▶ Active – situation or action specific triggers
  - ▶ Flags
  - ▶ Pop-ups
  - ▶ [Diagnostic Management Teams](#)

# Passive Clinical Decision Support

# What makes clinicians use passive CDS?


- ▶ In general passive CDS used infrequently
- ▶ Accessed for abnormal findings more often
- ▶ Accessed for unusual situations more often
- ▶ Accessed more often when there are changes in process



# Active Clinical Decision Support

# Barriers to Active CDS


- Physician Acceptance



- Coding molecular and pathology information for electronic health record



- Interoperability



- Cost





Physician

52%

Alert

Discern: (1 of 1)



PHARMACOGENOMICS ALERT

**WARNING:** Patient carries a genetic variant that influences clopidogrel (Plavix) metabolism, resulting in impaired responsiveness.

Discern: (1 of 1)



## PHARMACOGENOMICS ALERT

08:49:00 PDT

**WARNING:** Patient carries a genetic variant that influences clopidogrel (Plavix) metabolism, resulting in impaired responsiveness.

- Consider prasugrel (Effient) or other alternative therapy.
- Contact a clinical pharmacist for more information.

**RESULT:** NEXT Exome Cyp2C19 Result (Sendout)

**NOTE:** This is an experimental pharmacogenomics alert created for patients in the NEXT01 Exome sequencing study.

- You may receive an e-mail asking for your feedback on this alert.

Alert Action

☐ Cancel Order

☐ Override Alert

More Info

Discern: (1 of 1)



## PHARMACOGENOMICS ALERT

**WARNING:** Patient carries a genetic variant that influences clopidogrel (Plavix) metabolism, resulting in impaired responsiveness.

- Consider prasugrel (Effient) or other alternative therapy.

Discern: (1 of 1)



## PHARMACOGENOMICS ALERT

**WARNING:** Patient carries a genetic variant that influences clopidogrel (Plavix) metabolism, resulting in impaired responsiveness.

- Consider prasugrel (Effient) or other alternative therapy.
- Contact a clinical pharmacist for more information.

**RESULT:** NEXT Exome Cyp2C19 Result (Sendout)

October 24, 2013 08:49:00 PDT

**NOTE:** This is an experimental pharmacogenomics alert created for patients in the NEXT01 Exome sequencing study.

- You may receive an e-mail asking for your feedback on this alert.

Alert Action

☐ Cancel Order

☐ Override Alert

# Not All Alerts are Created Equal



## ► Process Questions

- Do alerts cause providers to change medication or management?
- What percent of providers override alerts?

## ► Usability Questions

- What do providers like/dislike about CDS alerts?
- What makes a CDS alert more likely to be used?

# Quality Active CDS




Specificity

Good design


Clinical Evidence

**Stakeholder  
Acceptance**

# Coding for Active CDS





# Interoperability for Active CDS



- “Interoperability is the ability of different information technology systems and software applications to communicate, exchange data, and use the information that has been exchanged.”

<http://www.himss.org/library/interoperability-standards/what-is>



# Interoperability for Active CDS







Figure courtesy of David Chou

# Draft 10 Year CMS/ONC Interoperability Roadmap



**Figure 1. Health IT Ecosystem**



Connecting Health and Care for the Nation, A Shared Nationwide Interoperability Roadmap, October, 2015;  
<https://www.healthit.gov/sites/default/files/hie-interoperability/nationwide-interoperability-roadmap-final-version-1.0.pdf>


# Active CDS costs



- ▶ What was the estimated development, implementation, and maintenance cost for active pharmacogenetic CDS at the University of Washington expressed as cost per alert?
  - ▶ \$ 0
  - ▶ \$46
  - ▶ \$460
  - ▶ \$4,600
  - ▶ \$46,000
  - ▶ ∞



# Active CDS costs



# Take Home Points

- ▶ Most pathology reports, including molecular pathology reports, are currently not formatted to facilitate pathology data sharing and effective electronic clinical decision support. Improvements are needed.
- ▶ The costs of building and maintaining clinical decision support networks are often ignored or minimized; however, these costs can be substantial, especially if clinical decision support is implemented independently at each health care institution. Dramatic improvements in data interoperability and inter-institution collaboration will be necessary to drive decision support costs down.